Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee

Phase 2

Completed

Conditions: Osteoarthritis, Knee

Interventions: Drug: Naproxen
Drug: PF-04457845

First Posted Date: 2009-09-22

Last Posted Date: 2017-09-19

Lead Sponsor: Pfizer

Target Recruit Count: 76

Registration Number: NCT00981357

Locations: 🇺🇸
Arthritis & Rheumatic Care Center, Miami, Florida, United States
🇺🇸
Miami Research Associates, Miami, Florida, United States
🇺🇸
Vince and Associates Clinical Research, Overland Park, Kansas, United States

and more 3 locations

Phase 1, Single and Multiple Doses Study of Sitaxentan in Japanese and Western Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Sitaxentan sodium/Placebo

First Posted Date: 2009-09-22

Last Posted Date: 2010-10-15

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT00981968

Locations: 🇺🇸
Pfizer Investigational Site, Glendale, California, United States

Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Phase 3

Completed

Conditions: Vaccines, Pneumococcal Conjugate Vaccine

Interventions: Biological: 13vPnC
Biological: 23vPS

First Posted Date: 2009-09-21

Last Posted Date: 2018-12-20

Lead Sponsor: Pfizer

Target Recruit Count: 251

Registration Number: NCT00980655

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸
Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, United States
🇺🇸
Columbia University Medical Center Research Pharmacy, New York, New York, United States

and more 44 locations

A Study to Investigate the Effect of ICA-105665 in Photosensitive Epilepsy Patients

Phase 2

Terminated

Conditions: Epilepsy

Interventions: Drug: ICA-105665

First Posted Date: 2009-09-17

Last Posted Date: 2012-10-04

Lead Sponsor: Pfizer

Target Recruit Count: 13

Registration Number: NCT00979004

Locations: 🇺🇸
Pfizer Investigational Site, Nashville, Tennessee, United States

A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: figitumumab
Drug: Cisplatin (Or Carboplatin)
Drug: Etoposide

First Posted Date: 2009-09-15

Last Posted Date: 2013-02-25

Lead Sponsor: Pfizer

Target Recruit Count: 9

Registration Number: NCT00977561

Locations: 🇪🇸
Pfizer Investigational Site, Valencia, Spain

A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

Phase 2

Terminated

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: PF-03463275

First Posted Date: 2009-09-15

Last Posted Date: 2012-02-07

Lead Sponsor: Pfizer

Target Recruit Count: 207

Registration Number: NCT00977522

Locations: 🇺🇸
Pfizer Investigational Site, Houston, Texas, United States

Study To Estimate The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Treatment A
Drug: Treatment B

First Posted Date: 2009-09-15

Last Posted Date: 2010-02-11

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT00977015

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

Phase 1

Terminated

Conditions: Colorectal Neoplasms
Lung Neoplasms
Breast Neoplasms
Prostatic Neoplasms
Sarcoma

Interventions: Drug: figitumumab
Drug: pegvisomant

First Posted Date: 2009-09-14

Last Posted Date: 2013-12-13

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT00976508

Locations: 🇩🇪
Pfizer Investigational Site, Muenster, Germany

A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: CP-690,550 + methotrexate
Drug: Placebo + Methotrexate

First Posted Date: 2009-09-14

Last Posted Date: 2013-01-09

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT00976599

Locations: 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States

A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users

Phase 1

Completed

Conditions: Alzheimer's Disease
Huntington's Disease

Interventions: Drug: dimebon
Drug: placebo
Drug: alprazolam

First Posted Date: 2009-09-11

Last Posted Date: 2013-04-02

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT00975481

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy